SEP 16, 2014 8:30 AM PDT

The use of transcriptional signatures for clinical population selection

Speaker

Abstract
The use of biomarkers for the stratification of populations for therapy is a concept that holds the potential to revolutionize clinical trial design, the economics of healthcare, and most importantly, the future treatment of cancer patients. While single-gene aberrations are currently being used as predictive biomarkers in oncology clinical trial design, the use of multi-gene biomarkers such as transcriptional signatures is not common, despite the fact that multi-gene signatures may be more likely to provide the high sensitivity and specificity required for biomarkers to be validated for clinical practice. The Compendia Bioscience Translational Bioinformatics Services team has expertise in generation and refinement of transcriptional biomarkers of response. These signatures of response and resistance can be utilized to support many aspects of drug development, including understanding mechanism of action, building a competitive differentiation plan, and identification of drug combination opportunities. In this session, Dr. Urick will discuss the potential utility of transcriptional signatures as predictive biomarkers as well as highlight the current techniques used by the Compendia Bioscience Translational Bioinformatics Services team to utilize transcriptional signatures for potential clinical trial population selection.

Show Resources
You May Also Like
JAN 23, 2020 9:00 AM PST
C.E. CREDITS
JAN 23, 2020 9:00 AM PST
DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
APR 07, 2020 8:00 AM PDT
C.E. CREDITS
APR 07, 2020 8:00 AM PDT
DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
FEB 26, 2020 9:00 AM PST
C.E. CREDITS
FEB 26, 2020 9:00 AM PST
DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
MAR 03, 2020 9:00 AM JST
C.E. CREDITS
MAR 03, 2020 9:00 AM JST
DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
FEB 25, 2020 9:00 AM PST
C.E. CREDITS
FEB 25, 2020 9:00 AM PST
Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
DEC 10, 2019 9:00 AM PST
C.E. CREDITS
DEC 10, 2019 9:00 AM PST
DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
Loading Comments...
Show Resources